EXP2SL: A Machine Learning Framework for Cell-Line-Specific Synthetic Lethality Prediction

Synthetic lethality (SL), an important type of genetic interaction, can provide useful insight into the target identification process for the development of anticancer therapeutics. Although several well-established SL gene pairs have been verified to be conserved in humans, most SL interactions rem...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 11; p. 112
Main Authors Wan, Fangping, Li, Shuya, Tian, Tingzhong, Lei, Yipin, Zhao, Dan, Zeng, Jianyang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.02.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Synthetic lethality (SL), an important type of genetic interaction, can provide useful insight into the target identification process for the development of anticancer therapeutics. Although several well-established SL gene pairs have been verified to be conserved in humans, most SL interactions remain cell-line specific. Here, we demonstrated that the cell-line-specific gene expression profiles derived from the shRNA perturbation experiments performed in the LINCS L1000 project can provide useful features for predicting SL interactions in human. In this paper, we developed a semi-supervised neural network-based method called EXP2SL to accurately identify SL interactions from the L1000 gene expression profiles. Through a systematic evaluation on the SL datasets of three different cell lines, we demonstrated that our model achieved better performance than the baseline methods and verified the effectiveness of using the L1000 gene expression features and the semi-supervise training technique in SL prediction.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Alex Zhavoronkov, Biogerontology Research Foundation, United Kingdom
Reviewed by: Feng ZHU, Zhejiang University, China; Vasileios Stathias, University of Miami, United States; Qi Zhao, Shenyang Aerospace University, China; Jihye Kim, University of Colorado Anschutz Medical Campus, United States; Bhaskar Roy, Beijing Genomics Institute (BGI), China
These authors have contributed equally to this work
This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2020.00112